10D5

10D5 (also known by the internal code name TM2a) is a murine monoclonal antibody (IgG1) that targets the N-terminal region of the amyloid $\beta$-peptide (A$\beta$), specifically binding to an epitope within residues 3-7. Developed by Athena Neurosciences (later Elan Pharmaceuticals), it was one of the first antibodies used to demonstrate that passive immunization could significantly reduce amyloid plaque burden and associated neuropathology in transgenic mouse models of Alzheimer's disease, such as the PDAPP mouse. The antibody works by crossing the blood-brain barrier, decorating amyloid plaques, and triggering microglial-mediated clearance through Fc receptor-mediated phagocytosis and subsequent peptide degradation. While 10D5 was a critical proof-of-concept molecule in the development of Alzheimer's immunotherapies, it was not the lead candidate selected for humanization; instead, the related antibody clone 3D6 was humanized to become bapineuzumab.

Other names

anti-Abeta 10D5anti-Abeta10D5anti-Abeta-10D5anti-Abeta antibody 10D5